证券代码：300463 证券简称：迈克生物 公告编号：2025-108 迈克生物股份有限公司 关于持股 5%以上股东减持股份触及 1%及 5%整数倍 暨披露简式权益变动报告书的提示性公告 3、本次权益变动后，郭雷先生持有公司股份 30,233,231 股，占公司总股本的 4.99998%， 不再是公司持股 5%以上股东。 迈克生物股份有限公司（以下简称"公司"或"迈克生物"）于 2025 年 11 月 26 日披露了《关 于公司持股 5%以上股东减持计划的预披露公告》，公司持股 5%以上股东郭雷先生计划自 2025 年 12 月 18 日至 2026 年 3 月 17 日（窗口期不减持），合计通过集中竞价方式减持不超过 500,000 股 公 司 股 份 ， 即 不 超 过 公 司 当 前 总 股 本 的 0.08% 。 详 见 公 司 披 露 于 巨 潮 资 讯 网 (www.cninfo.com.cn)的相关公告，公告编号：2025-104。 一、减持的具体情况 公司于今日收到持股 5%以上股东郭雷先生出具的《关于减持公司股份计划进展情况的告 知函》和《简式权益变动报告书》，获悉郭雷先生于 2025 年 ...

Core Viewpoint - The company, Maike Bio (300463), has adopted a pricing strategy that combines "equipment + software + reagents + services" based on the differences in hospital scale, procurement entities, and cooperation models [1] Group 1 - The company responds to investor inquiries on its interactive platform regarding its revenue structure [1] - The specific details of the revenue structure can be found in the company's periodic reports [1]

Group 1 - The company, Maike Bio (300463.SZ), currently has no plans to issue convertible bonds [1]

格隆汇12月17日丨迈克生物(300463.SZ)在投资者互动平台表示，公司目前暂无发行可转债的计划。 ...

Core Viewpoint - The company has successfully implemented smart laboratory systems in 9 hospitals and is in the process of implementing in 12 more, with expectations for significant growth in contracts in the upcoming quarter [1] Group 1: Implementation Progress - As of the end of Q3 this year, 9 hospitals are actively running smart laboratory systems [1] - 12 additional hospitals are currently in the implementation process [1] - Several other hospitals are in the early stages of design for the smart laboratory systems [1] Group 2: Market Reach and Future Projections - The company aims to cover various levels of hospitals, including tertiary, secondary, and county-level hospitals, to achieve the deployment of smart laboratories in multiple scenarios [1] - It is anticipated that the number of signed contracts for smart laboratories will exceed 100 in the first quarter of next year [1] - The company's main clients are not limited to Sichuan Province but also include other provinces and cities across the country [1]

格隆汇12月15日丨迈克生物(300463.SZ)在投资者互动平台表示，公司此前展示的人形智能机器人是公 司我的实验室智能合作伙伴——MICO（My Intelligent Cooperator）的一种形式，是我们在实验室自动 化与智能化领域的一次创新探索，旨在探索未来智慧实验室的解决方案。目前该产品仍处于研发验证和 场景适配的初级阶段。公司暂无设立、参股智能机器人公司的计划。感谢您的关注与支持！ 风险提 示：人工智能机器人在医疗场景的应用仍面临技术迭代、监管审批、市场接受度等多重挑战，其研发成 果转化存在不确定性。 ...

Core Viewpoint - The humanoid intelligent robot showcased by the company is a product developed in collaboration with a third-party partner, MICO, and is currently in the early stages of research and development [1] Group 1 - The humanoid intelligent robot is based on a third-party robot product and is specifically designed for smart laboratory applications [1] - The product is still in the initial phase of research validation and scenario adaptation [1]

Core Viewpoint - The company has successfully implemented smart laboratory systems in 9 hospitals and is in the process of implementing in 12 more, indicating a growing adoption of customized solutions in the healthcare sector [2] Group 1: Company Developments - As of the end of Q3 this year, 9 hospitals are operating smart laboratory systems [2] - 12 hospitals are currently in the implementation phase of the smart laboratory systems [2] - Several other hospitals are in the early stages of design for smart laboratory solutions [2] Group 2: Industry Trends - The smart laboratory systems differ from traditional single-unit systems by offering customizable designs and services based on the specific needs of different hospitals [2] - The company emphasizes that it is challenging to predict the exact outcomes and calculations for the implementation of these systems [2]

Group 1 - The company has implemented smart laboratory systems in 9 hospitals as of the end of Q3 this year, with 12 more in the implementation phase and several others in the early design stage [1] - The difference between the production line and smart laboratories compared to traditional single machines is that they offer customized design and services based on the actual conditions of different hospitals, making it difficult to predict exact calculations [1]

Group 1 - Dingyang Technology has launched the SPB3000X series source load simulator, which includes three models: SPB3100X, SPB3200X, and SPB3300X, featuring high precision, low ripple noise, and fast transient response [1] - Ningbo Huaxiang plans to acquire 40% of Fengmei Power's equity from SAIC Volkswagen, with the total acquisition involving 100% equity [2] - ST Jiaotou will implement a capital reserve conversion to increase share capital, with a total of 267 million shares to be converted [3] Group 2 - Century Huatong's subsidiary Guosheng Capital holds 19.5887 million shares of Moer Thread, accounting for 4.8968% of the total share capital before the IPO [4] - Meidike intends to introduce strategic investors to its subsidiary, with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [5] - Baiyun Airport reported a 12.58% year-on-year increase in passenger throughput in November, totaling 7.3228 million passengers [6] Group 3 - Shengda Resources' subsidiary Honglin Mining has received approval for a three-month extension for trial production [7] - ST Yigou's subsidiary Suning International is expected to increase net profit by approximately 992 million yuan from the sale of eight subsidiaries [8][9] - Huayi Brothers reported overdue debts totaling 52.5 million yuan, exceeding 10% of its audited net assets for 2024 [10] Group 4 - Wanshun New Materials plans to acquire 100% of Eurofoil Luxembourg for 12.3889 million euros, enhancing its aluminum foil production capabilities [11] - Wuhan Tianyuan's subsidiary plans to invest approximately 600 million yuan in two energy storage projects [12] - Maike Biological's subsidiary has received a product registration certificate for a new automatic cell morphology analyzer [13] Group 5 - CATL intends to register for the issuance of bonds not exceeding 10 billion yuan, primarily for project construction and working capital [14] - Yuntianhua plans to acquire 100% of Tianyao Chemical for 36.8858 million yuan, enhancing its fine phosphorus chemical product line [15] - Fucheng Technology's controlling shareholder has reduced its stake by 1.0429 million shares [16] Group 6 - Zhili Fang plans to reduce its stake by up to 1.2% of the company's total shares [17][18] - Qianzhao Optoelectronics' chairman intends to reduce his stake by up to 0.02% [19] - Sanmu Group's subsidiary plans to sell 75 office properties for 24.1068 million yuan [20] Group 7 - Zhuangyuan Pasture's director plans to reduce his stake by up to 3% of the company's total shares [21] - Chongqing Pharmaceutical's subsidiary has signed a licensing agreement with Pfizer, potentially earning up to 50 million USD in milestone payments [22] - Yongqing Environmental Protection's shareholder plans to reduce its stake by up to 1% [23] Group 8 - Lens Technology plans to acquire 100% of PMG International Co., Ltd., enhancing its capabilities in server cabinet business [24] - Xinbang Pharmaceutical is facing prosecution for alleged unit bribery, but its control remains unchanged [25] - Meian Health's shareholders plan to reduce their stake by up to 3% of the company's total shares [26] Group 9 - Central Plaza's subsidiary has decided to suspend operations due to ongoing operational difficulties [27] - Dawn Co. plans to acquire 80% of Ningbo Aisikai for 516 million yuan, including the transfer of related patents and technologies [28] - Kweichow Moutai will distribute over 30 billion yuan in cash dividends based on its 2025 mid-term profit distribution plan [29] Group 10 - Baiyun Airport has received approval from the CSRC for a stock issuance to specific targets [29] - Zai Sheng Technology reported that revenue from aerospace-related products will account for less than 0.5% of its total revenue in 2024 [30]